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A Ab bs st tr ra ac ct t    Natural botanical products can be integrated with western medicine to 
optimize the treatment outcome, increase immune function and minimize 
the side effects from western drug treatment. CKBM is a combination of 
herbs and yeasts formulated based on traditional Chinese medicinal 
principles. Previous study has demonstrated that CKBM is capable of 
improving immune responsiveness through the induction of cytokine 
mediators, such as TNF-α and IL-6. In this study, we aimed to investigate the 
e f f e c t  o f  t h i s  i m m u n o m o d u l a t o r y  d r u g  o n  g a s t r i c  c a n c e r  g r o w t h  u s i n g  a  
human xenograft model. Gastric cancer tissues were implanted 
subcutaneously into athymic nude mice followed by a 14-day or 28-day of 
CKBM treatment. Results showed that higher doses of CKBM (0.4 or 0.8 
ml/mouse/day) produced a dose-dependent inhibitory effect on gastric 
tumor growth after 28-day drug treatment. This was associated with a 
decrease of cellular proliferation by 30% with concomitant increase in 
apoptosis by 97% in gastric tumor cells when compared with the control 
group. In contrast, CKBM showed no effect on angiogenesis in gastric 
tumors. This study demonstrates the anti-tumorigenic action of CKBM on 
gastric cancer probably via inhibition of cell proliferation and induction of 
apoptosis, and provides future potential targets of this drug candidate on 
cancer therapy. 
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1.  Introduction 
Natural botanical products have a long history in the world and are featured in using a complex 
combination of herbs to treat various diseases (e.g. rheumatoid arthritis, menopausal symptoms, colds 
and flu etc). CKBM-A01 is a combination of herbs including Wu Wei Zi (Schisandra chinensis), 
Ginseng (Panax ginseng), Hawthorn (Fructus Crataegi), Jujube (Ziziphus jujube), Soybean (Glycine 
Max) and Saccharomyces cerevisiae (baker’s yeast), which is formulated based on traditional Chinese 
medicinal principles and processed by a proprietary technology developed by CK Life Sciences Limited 
(CKLS).  
Schisandra chinensis has been shown to suppress the TPA-induced skin tumor formation and 
prostate carcinogenesis [1, 2]. It also aids to protect liver from injury, stimulates liver regeneration and 
reduces inflammation. Panax ginseng and Ziziphus jujube provide several pharmacological activities 
like modulating immune system and anti-stress activities [3]. The levels of cytokines (e.g. tumor 
necrosis factor-α, IL-1β, IL-6, interferon-γ) and reactive oxygen/nitrogen production were enhanced by 
these compounds to exert phagocytic activity [4]. Isoflavone-containing compound like soybean has 
been shown to lower estrogen levels, which helps to prevent and reduce the risk of breast cancer [5]. In 
addition, extracts of soybean suppressed F3II mouse mammary adenocarcinoma cell growth in vivo and 
in vitro through the G2/M cell cycle arrest [6].   
In this study, we aimed to determine the effect of CKBM-A01 (a combined recipe of the above 
mentioned Chinese herbs and yeast) on the growth of human gastric cancer using a unique 
subcutaneous implantation model of gastric cancer tissue. In this connection, CKBM was given at 
different doses to investigate the effect on tumor growth. To further examine the anti-tumor mechanism, 
the three important biological parameters in tumorigenesis including cell proliferation and apoptosis [7], 
and also angiogenesis [8] were assessed in gastric tumors after drug treatment.   
2.  Materials and methods 
Chemicals and reagents 
CKBM-A01 (Batch no.: 0212201) was provided by CKLS (Hong Kong, China). The product is in 
liquid form.  All chemicals and reagents were purchased from Sigma (Sigma Chemical Company, St 
Louis, USA) unless otherwise specified.  
Cell culture 
Human gastric carcinoma cell line (MKN-28) was purchased from RIKEN (The Institute of 
Physical and Chemical Research) Cell Bank, Japan. Cells were cultured in RPMI 1640 medium 
(GibcoBRL, USA) supplemented with 10% fetal bovine serum (BibcoBRL), 100 U/mL penicillin G, 
100 µg/mL streptomycin, and maintained in a humidified 5% CO2 atmosphere at 37°C. 
Experimental animals and tumor implantation  
Female athymic balb/c nude mice (Charles River Laboratories Ltd., USA), aged 4-6 weeks and 
weighing 19-24 g, were used in the tumor implantation model. They were housed in IVC cages of 
isolated ventilation to avoid microbial contamination. Gastric cancer tissues (1.5 mm
3) were implanted 
subcutaneously (s.c.) into the right dorsal area of mice. Ten days after implantation, animals were 
randomized into 4 treatment groups: control group (0.8 ml distilled water/mouse) and CKBM-A01 (0.2, 
0.4 or 0.8 ml/mouse) treatment groups. They were fed intragastrically (i.g.) daily for 14 and 28 days.  
Tumor areas were measured every 7 days using a caliper, and the tumor area was calculated 
according to the formula: tumor volume (mm
3) = d
2 x D/2, where d and D were the shortest and the 
longest diameter respectively [9]. 
Assessment of cell proliferation 
Paraffin-embedded tumor samples that had been fixed in formalin were cut into sections of 5 µm. 
Sections were incubated in citrate buffer (0.01 M, pH 6.0) at 80°C for 15min and followed by digestion 
using pepsin (0.005%) in HCl (0.01 N, pH 2.0). After washing with PBS (0.01 M, pH 7.4), sections 
were incubated with normal serum (LSAB kit, DAKO, Copenhagan, Denmark) for 60 min. After 
blocking, they were incubated with a monoclonal primary antibody against mouse proliferating cell Int. J. Med. Sci. 2004 1(3): 137-145  139 
nuclear antigen (PCNA, 1:200) (Santa Cruz Biotechnology, Santa Cruz) for 90 min, and then incubated 
with Link reagent (LSAB kit, DAKO) for 60 min at room temperature. Sections were incubated with 
Streptavadin (LSAB kit, DAKO) for 60 min, and further incubated with hydrogen-peroxidase-
diaminobenzidine (H2O2-DAB) to visualize the PCNA-positive cells. Finally, they were counterstained 
with Mayer’s hematoxylin. The total number of proliferating cells in a total of ten fields (x 400) across 
and perpendicular at the center of the tumor was counted under the microscope. The results of cell 
proliferation were expressed as the number of PCNA-positive cells per field [10]. The same approach 
was adopted for measuring apoptosis and angiogenesis in the tumors. 
Assessment of angiogenesis 
Microvessel density was assessed by immunostaining as described previously [11] with 
modifications. Sections were digested with trypsin for 30 min at room temperature and incubated with a 
blocking agent (LSAB kit, DAKO, Copenhagen, Denmark) for 1 hr. They were then incubated with a 
rabbit anti-human von Willebrand factor (DAKO, Copenhagan, Denmark) with a dilution of 1:200 
overnight at 4°C. After washing with PBS (0.01 M, pH 7.4), sections were incubated with Link reagent 
(LSAB kit, DAKO) for 1 hr, followed by streptavidin (LSAB kit, DAKO) for another 1 hr. Sections 
were incubated with hydrogen-peroxidase-diaminobenzidine to visualize the microvessels. The results 
of microvessel density were expressed as the number of microvessel per field (x 200).   
Assessment of apoptosis 
Epithelial cell apoptosis was detected from paraffin-embedded tissue sections by the terminal 
deoxynucleotidyltranferase-mediated dUTP nick end–labeling (TUNEL) method as described 
previously [12]. Tissue sections were digested with 20 µg/ml proteinase K for 20 min at 37°C and 
treated with 0.3% H2O2 solution at room temperature. Afterwards, they were incubated with TdT buffer 
containing 40 U/ml TdT and 5 nmol/ml biotinylated-dUTP, and kept in humidified atmosphere for 90 
min at 37°C. The reaction was quenched by washing with terminating buffer (300 mM sodium chloride 
and 30 mM sodium citrate) for 15 min. After blocking with normal serum, sections were incubated with 
peroxidase-labeled streptavidin for 30 min and stained with diaminobenzidine-H2O2 for 10 min. Finally, 
the sections were counterstained with Mayer’s hematoxylin. For positive control, sections were treated 
with 0.5 U/ml DNase I in Dnase buffer (10 mM NaCl, 50 mM MnCl2, 0.1 mM CaCl2, 25 mM KCl and 
10 mM Tris-HCl, pH 7.4) for 10 min; whereas negative control was prepared with the omission of TdT. 
The number of apoptotic cells in a total of ten fields (x 400) per tumor was counted under microscope.  
The results of apoptotic cells were expressed as the number of apoptotic cells per field. 
Statistical analysis   
Statistical significance between the treatment groups was analyzed using a two-way statistical 
analysis of variance (ANOVA), followed by Dunnett t-test and post-hoc analysis when necessary.  
3.  Results 
Effect of CKBM treatment on gastric tumor growth 
All the control (water vehicle-treated) and CKBM-treated mice developed subcutaneous tumor 
after gastric cancer tissue implantation. Figures 1A & 1B show the effect of CKBM on tumor growth 14 
days or 28 days after treatment. The tumor growth of the control group increased steadily during the 14- 
and 28-day experimental periods.  Results showed that CKBM exhibited a dose-dependent inhibition on 
tumor growth starting from Day 7 onwards. There was a significant 50% reduction on tumor growth in 
the CKBM-treated groups at doses of 0.4 and 0.8 ml/mouse on Day 21 and Day 28 after drug treatment 
(Figure 1B) when compared with the corresponding control group. CKBM did not affect the body 
weight changes in these animals during the experimental period.    
Effect of CKBM treatment on angiogenesis in gastric tumors 
There was an increase in the microvessel density from Day 14 to Day 28 in the control group, 
implicating that angiogenesis is essential in the development of tumors (Figures 2A & 2B). However, 
CKBM treatment for 14 and 28 days did not produce dose-dependent effect on angiogenesis in gastric 
tumors. Notably, CKBM at all doses, except 0.4 ml/mouse, significantly increased angiogenesis in Int. J. Med. Sci. 2004 1(3): 137-145  140 
gastric tumors after 14 days of drug treatment (Figure 2A). In contrary, the stimulatory effect of CKBM 
on angiogenesis was not observed after 28 days of treatment although the highest dose of CKBM (0.8 
ml/mouse) had a trend of decrease in angiogenesis but did not have statistical significance (Figure 2B).    
Effect of CKBM treatment on apoptosis of cancer cells in gastric tumors 
There was no significant effect on the number of apoptotic cells in the gastric tumors after 14 days 
of drug treatment (Figure 3A). However, prolonged treatment of CKBM to 28 days dose-dependently 
exhibited an induction of apoptosis in gastric cancer cells. At doses of 0.4 and 0.8 ml/mouse of CKBM 
treatment, apoptosis was significantly increased by 76% and 97% respectively when compared with the 
corresponding control group (Figure 3B).  
Effect of CKBM treatment on cell proliferation of cancer cells in gastric tumors 
The anti-proliferative effect of CKBM treatment was observed as early as 14 days after drug 
treatment. The highest dose of 0.8 ml/mouse significantly reduced the number of cell proliferation in 
the gastric tumors by 30% when compared with the control group (Figure 4A). Similarly, prolong 
treatment of CKBM to 28 days dose-dependently inhibited the number of proliferative cells in gastric 
tumors (Figure 4B).   
4.  Discussion 
In this study, CKBM significantly inhibited the growth of gastric tumor in human xenografts 
model using MKN-28 cells (Figures 1A & 1B). The efficacy of CKBM exhibited a dose-dependent 
manner in this ex-vivo model during the 28-day experimental period and exerted the inhibitory action as 
early as 21 days after drug treatment (Figure 1B). The effective doses of CKBM were found to be 0.4 
and 0.8 ml/mouse, which significantly reduced the number of PCNA-positive cells and increased the 
apoptotic cells in the tumor tissues (Figures 3B & 4B). In contrast, CKBM did not affect angiogenesis 
at the time when it inhibited tumor growth (Figures 2A & 2B), although it increased with time along 
with tumor development in the control group. These findings implicated that CKBM suppressed gastric 
cancer growth specifically through the reduction of cell proliferation and promotion of apoptosis in this 
model.  
Dietary supplement containing Schisandra chinensis has been shown to reduce prostate cancer cell 
growth and induce apoptosis by inhibiting androgen receptor expression [1]. Besides, soybeans contain 
various anti-carcinogenic compounds including lunasin and lectins that were shown to induce apoptosis 
in malignant cells [13].  As CKBM contains these compounds, this would partially explain why it 
inhibits tumor growth in the present animal model. Besides, CKBM may also inhibit cancer xenograft 
growth via cytokine secretion. Panax ginseng and Ziziphus jujube, the other major components in 
CKBM, induce cytokine release in macrophages [4]. Moreover, soluble β-glucans from Saccharomyces 
cerevisiae could activate macrophage to secrete TNF-α [14], which is found to have a pro-apoptotic 
effect on human cancer cells [15].  Anti-cancer drugs such as sulindac and its metabolite have been 
shown to augment TNF-α-mediated cell death signaling pathway through the blockade of NF-κB in 
human carcinoma cells [16]. Previous study also shows that CKBM is able to modulate the immune 
response through the induction of TNF-α and IL-6 secretion in peripheral blood mononuclear cells [17].  
Although nude mice are immune deficient animals, there is evidence that cytokines are inducible in 
these animals. To this end, previous studies show that TNF-α can be induced and detected in the serum 
and splenocytes from nude mice after drug treatment such as 5-FU [18, 19, 20].  It is therefore possible 
that CKBM could induce cytokine release including TNF-α in these animals and inhibit tumor growth. 
However, further study is needed to determine how they are induced and the mechanisms they inhibit 
cancer cell growth in vivo.  
In summary, CKBM is a mixture of natural herbs and yeast that is effective to reduce the growth of 
gastric tumors in nude mice. The anti-tumorigenic action of CKBM is perhaps through the induction of 
apoptosis and inhibition of proliferation of gastric cancer cells. However, further clinical trials in 
humans are needed to examine the pharmacokinetics and the therapeutic action of CKBM on cancer 
patients. 
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Figures 
Figure 1. Effect of CKBM treatment (0.2, 0.4 or 0.8 ml/mouse, given i.g. once daily) for (A) 14 days; 
(B) 28 days on gastric tumor growth in Balb/c nude mice (*P<0.05 when compared with the 
corresponding control group).  Values are means ± SEM of 10-14 mice per group. 
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Figure 2. Effect of CKBM treatment (0.2, 0.4 or 0.8 ml/mouse, given i.g. once daily) for (A) 14 days; 
(B) 28 days on number of blood vessels in gastric tumors (*P<0.05, **P<0.01 when compared with the 
corresponding control group). Values are means ± SEM of 4-14 mice per group. 
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Figure 3. Effect of CKBM treatment (0.2, 0.4 or 0.8 ml/mouse, given i.g. once daily) for (A) 14 days; 
(B) 28 days on number of apoptotic cells in gastric tumors (*P<0.01 when compared with the control 
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Figure 4. Effect of CKBM treatment (0.2, 0.4 or 0.8 ml/mouse, given i.g. once daily) for (A) 14 days; 
(B) 28 days on number of proliferative cells in gastric tumors (*P<0.05, **P<0.01 when compared with 
the corresponding control group). Values are means ± SEM of 4-13 mice per group. 
 